Friedbert Weiss, Ph.D.
Institution:
Scripps Research Institute, La Jolla, La Jolla, CA, United StatesDepartment:
Department of NeuroscienceArea:
Neuroscience of AddictionWebsite:
http://www.martintrailer.com/science/photohtml/weissMidFrame.htmlGoogle:
"Friedbert Weiss"Bio:
http://www.scripps.edu/research/faculty.php?rec_id=3219
Mean distance: 12.76 (cluster 19) | S | N | B | C | P |
Parents
Sign in to add mentor| Paul Ekman | research assistant | 1979-1981 | UCSF |
| Aaron Ettenberg | grad student | 1982-1986 | UC Santa Barbara |
| Roberta Lou Klatzky | grad student | 1982-1986 | UC Santa Barbara |
| Loy D. Lytle | grad student | 1982-1986 | Scripps Institute |
| Floyd E. Bloom | post-doc | Scripps Institute | |
| George F. Koob | post-doc | 1986-1988 | Texas A&M University, The Scripps Research Institute |
| Urban Ungerstedt | research scientist | Karolinska |
Children
Sign in to add traineeCollaborators
Sign in to add collaborator| GianLuigi Gessa | collaborator | Scripps Institute | |
| Rueben A. Gonzales | collaborator | Scripps Institute | |
| Yasmin Hurd | collaborator | Karolinska | |
| Regina Richter | collaborator | Scripps Institute | |
| Fernando Rodriguez De Fonseca | collaborator | Scripps Institute | |
| Roberto Ciccocioppo | collaborator | 2000- | Scripps Institute |
BETA: Related publications
See more...
Publications
|
You can help our author matching system! If you notice any publications incorrectly attributed to this author, please sign in and mark matches as correct or incorrect. |
| Cannella N, Lunerti V, Shen Q, et al. (2024) Cebranopadol, a novel long-acting opioid agonist with low abuse liability, to treat opioid use disorder: Preclinical evidence of efficacy. Neuropharmacology. 110048 |
| Petrella M, Borruto AM, Curti L, et al. (2024) Pharmacological blockage of NOP receptors decreases ventral tegmental area dopamine neuronal activity through GABA receptor-mediated mechanism. Neuropharmacology. 248: 109866 |
| Lunerti V, Shen Q, Li H, et al. (2023) Cebranopadol, a novel long-acting opioid agonist with low abuse liability, to treat opioid use disorder: Preclinical evidence of efficacy. Biorxiv : the Preprint Server For Biology |
| Kozanian OO, Nedelescu H, Kufahl PR, et al. (2022) Compulsive Alcohol Seeking and Relapse: Central Role of Conditioning Factors Associated with Alleviation of Withdrawal States by Alcohol. British Journal of Pharmacology |
| Laque A, Wagner GE, Matzeu A, et al. (2022) Linking drug and food addiction via compulsive appetite. British Journal of Pharmacology |
| Nedelescu H, Wagner GE, De Ness GL, et al. (2021) Cannabidiol Produces Distinct U-Shaped Dose-Response Effects on Cocaine-Induced Conditioned Place Preference and Associated Recruitment of Prelimbic Neurons in Male Rats. Biological Psychiatry Global Open Science. 2: 70-78 |
| Ubaldi M, Cannella N, Borruto AM, et al. (2021) Role of Nociceptin/Orphanin FQ-NOP Receptor System in the Regulation of Stress-Related Disorders. International Journal of Molecular Sciences. 22 |
| Domi A, Lunerti V, Petrella M, et al. (2021) Genetic Deletion or Pharmacological Blockade of Nociceptin/Orphanin FQ Receptors in the Ventral Tegmental Area Attenuates Nicotine-Motivated Behaviour. British Journal of Pharmacology |
| Borruto AM, Fotio Y, Stopponi S, et al. (2021) NOP receptor antagonism attenuates reinstatement of alcohol-seeking through modulation of the mesolimbic circuitry in male and female alcohol-preferring rats. Neuropsychopharmacology : Official Publication of the American College of Neuropsychopharmacology |
| Borruto AM, Stopponi S, Li H, et al. (2021) Genetically Selected Alcohol-Preferring msP Rats to Study Alcohol Use Disorder: Anything Lost in Translation? Neuropharmacology. 108446 |